Non-Executive Director

RNS Number:3439F
Ardana PLC
29 June 2006

                       ARDANA APPOINTS NEW NON-EXECUTIVE
                                  TO THE BOARD



Edinburgh, UK, 29 June, 2006;  Ardana, the company focused on improving human
reproductive health, today announces that Huw Jones has been appointed as a
non-executive director.



Huw Jones was awarded a PhD in Pharmacology 1986. After a short period of
postdoctoral research, he joined Smith Kline & French UK in a commercial role in
1986. During his eleven-year career at SK&F and SmithKline Beecham he migrated
through a number of sales, marketing, business development and new product
development roles of increasing seniority. He was appointed UK Marketing
Director in 1996.



Huw moved to Elan Corporation PLC in 1997. In 1998 he was appointed
Vice-President and Managing Director, UK and in 2001 was appointed Senior Vice
President, Northern Europe, responsible for operations in Germany, France,
Ireland, the UK and for establishing companies in Benelux.



In 2002 he co-founded Daffodil Consulting LLP which specialises in providing
strategic advice on Europe to biopharmaceutical companies. Daffodil Consulting
was asked to establish the European affiliate for CV Therapeutics Inc (NASDAQ,
CVTX) in late 2002. Huw served as President, Europe, for CV Therapeutics between
2002 and 2006. He is also Non-Executive Chairman of Ashbourne Pharmaceuticals.



Maureen Lindsay, CEO of Ardana, said:



"Huw brings considerable sales and marketing expertise to our Board and we are
delighted that he is joining us. He has an impressive background and his current
directorships demonstrate how highly he is valued in an advisory capacity. His
contributions will be invaluable as we grow our commercial product pipeline
across Europe."





For more information contact:




Ardana                                     Financial Dynamics
Maureen Lindsay                            (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550                 Julia Phillips/John Gilbert
                                           Tel: +44 (0)20 7831 3113





About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
outlicensing to maintain a robust pipeline.



Ardana's four lead products are summarised below:



  * StriantTM SR, a testosterone replacement therapy that has already been
    launched by Ardana through its own sales force in the UK as a treatment for
    men with hypogonadism and for which Ardana has marketing rights in Europe;
  * Teverelix LA, in development for three initial indications (prostate
    cancer, BPH and endometriosis);
  * Testosterone Cream, a trans dermal testosterone delivery system in
    development for the treatment of male hypogonadism, and is in Phase II
    trials;
  * Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.



In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana is listed on the Main Market of the London Stock Exchange.



For further information please see www.ardana.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAAKFKPFBKDDAB

Aura Renewable Acquisiti... (LSE:ARA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024